A detailed history of China Universal Asset Management Co., Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 15,711 shares of LEGN stock, worth $631,267. This represents 0.09% of its overall portfolio holdings.

Number of Shares
15,711
Previous 9,597 63.71%
Holding current value
$631,267
Previous $425,000 80.0%
% of portfolio
0.09%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$43.55 - $59.88 $266,264 - $366,106
6,114 Added 63.71%
15,711 $765,000
Q2 2024

Jul 19, 2024

SELL
$39.5 - $57.22 $224,952 - $325,867
-5,695 Reduced 37.24%
9,597 $425,000
Q1 2024

Apr 29, 2024

BUY
$55.06 - $69.99 $334,214 - $424,839
6,070 Added 65.82%
15,292 $858,000
Q4 2023

May 21, 2024

SELL
$57.25 - $69.74 $347,507 - $423,321
-6,070 Reduced 39.69%
9,222 $554,000
Q4 2023

Jan 23, 2024

BUY
$57.25 - $69.74 $410,711 - $500,314
7,174 Added 350.29%
9,222 $555,000
Q3 2023

May 21, 2024

BUY
$63.16 - $76.5 $75,728 - $91,723
1,199 Added 141.22%
2,048 $137,000
Q3 2023

Oct 30, 2023

BUY
$63.16 - $76.5 $75,728 - $91,723
1,199 Added 141.22%
2,048 $138,000
Q2 2023

May 21, 2024

SELL
$46.28 - $75.01 $1,342 - $2,175
-29 Reduced 3.3%
849 $58,000
Q2 2023

Jul 27, 2023

SELL
$46.28 - $75.01 $1,342 - $2,175
-29 Reduced 3.3%
849 $59,000
Q1 2023

May 21, 2024

BUY
$43.42 - $57.37 $9,552 - $12,621
220 Added 33.43%
878 $42,000
Q1 2023

Apr 27, 2023

BUY
$43.42 - $57.37 $9,552 - $12,621
220 Added 33.43%
878 $42,000
Q4 2022

May 21, 2024

SELL
$38.8 - $55.46 $567,799 - $811,601
-14,634 Reduced 95.7%
658 $32,000
Q4 2022

Jan 31, 2023

BUY
$38.8 - $55.46 $6,169 - $8,818
159 Added 31.86%
658 $33,000
Q3 2022

Oct 21, 2022

BUY
$38.15 - $57.1 $19,036 - $28,492
499 New
499 $20,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.